BIOCODEX
17.11.2022 18:09:39 CET | Business Wire | Press release
Biocodex, an expert in microbiota and women's health, announces that it has acquired a majority stake in Hilma, a start-up specializing in natural remedies in the United States. This acquisition is a key part of the Group’s international growth strategy and will enable Biocodex to consolidate its presence in the digestive health and women's health segments of the US market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005739/en/
Hilma, founded by entrepreneurs Hilary Quartner, Nina Mullen, and Lily Galef, launched in January 2020 with the ambition to reimagine the medicine cabinet with effective, natural alternatives to OTC products. Hilma makes natural remedies for digestive issues, sleep, immune support, and more. Since launch, the digitally native brand has built a strong community around its best-selling digestive portfolio. They have expanded their product line to encompass everything from bloating to occasional constipation and have become a fixture in the digestive aisle at Target, among other retailers.
The Biocodex Group has been present in the US for over 20 years and is a leader in the pharmacy market with its Florastor® brand in the probiotics category. Through this acquisition, the Group aims to strengthen its position in this segment and launch its women's health activity in order to double its turnover by 2027.
Julien Dureisseix, GM of the US subsidiary, is delighted with this acquisition: "Behind Hilma, there is a simple observation: a new generation of consumers has high expectations for natural and effective products." Nicolas Coudurier, CEO of Biocodex, adds: "Hilma and Biocodex share the same goal: to be as close as possible to consumers expectations and to respond to the growing need for reliable, effective and scientifically proven natural solutions in the medicine cabinet. I am very pleased to welcome a talented team whose entrepreneurial vision and digital expertise will be invaluable in strengthening our presence in the North American market."
Nina Mullen, Co-CEO of Hilma says, “Our partnership with The Biocodex Group will enable Hilma to rapidly scale our omnichannel retail strategy, reach new audiences, and develop new products.” Hilary Quartner, Co-CEO adds, “We are thrilled to join the Biocodex family, as they share our core values of commitment to scientifically backed, natural healthcare, and building a sustainable future.” “We look forward to learning from each other and exponentially growing Hilma and The Biocodex Group brands in the US.”, notes Lily Galef, Chief Brand Officer.
ADDITIONAL INFORMATION
About Biocodex
Biocodex is a French pharmaceutical company founded in 1953 to develop and market the world’s first probiotic yeast strain, Saccharomyces boulardii CNCM I-745®. Today, Biocodex focuses its business on three main areas: Microbiota care; Orphan diseases; Women’s health. With 1,600 employees, Biocodex generated net revenues of €418 million in 2021, including 42% in France and 58% internationally. The group is present in 124 countries through wholly owned subsidiaries in 16 countries and a network of distributors worldwide.
About Hilma
Hilma makes natural remedies that actually work for health issues like digestion, head tension, immune support and more. Hilma’s remedies are made with powerful herbs and minerals, formulated with a team of doctors, and backed by clinical research. Unlike most over-the-counter options, Hilma is made without drugs, dyes, fillers, preservatives, or artificial sweeteners. The company makes natural remedies accessible to a mainstream customer, who has embraced natural products in food, beauty, and household items, and is looking for an effective natural option for their medicine cabinet. Hilma is entirely female-founded and led. Hilma is an omnichannel brand, sold DTC on hilma.co as well as in 750+ stores, including Target, Grove Collaborative, Thrive Market, Juice Press, and Amazon.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005739/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Industry Study Finds Quantum Computing Has Entered a Capability Era, With Early Movers Building an Advantage Later Entrants Will Struggle to Close18.6.2026 09:00:00 CEST | Press release
State of Quantum 2026, based on tracked transaction data, a survey of 107 practitioners, and 19 interviews, finds 89% of enterprises surveyed are now hands-on with quantum but only 3% have reached scaled deployment, as the market shifts from accessing quantum systems to building capability around them. Quantum computing has moved past the question of whether organizations can access a quantum system and onto whether they can build something useful around one. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618639340/en/ State of Quantum 2026 is based on independently conducted research and analysis, authored by The Quantum Insider (Resonance), published by IQM Quantum Computers, and supported by OpenOcean. According to the State of Quantum 2026, the fourth annual industry study published today by IQM Quantum Computers, which is nearing its planned listing on the Nasdaq Global Select Market through its merger with Real Asse
Climate Clock Public Art Trail Opens Across Oulu18.6.2026 08:45:00 CEST | Press release
A major contemporary public art trail exploring climate, time and nature has opened across the Oulu region in Northern Finland as part of Oulu2026 European Capital of Culture. The permanent Climate Clock art trail brings together seven internationally recognised artists in site-specific works across forests, rivers, coastlines, urban environments and cultural heritage sites. The works reflect on climate change and different perceptions of time through sculpture, ceramics, natural materials, sound and kinetic forms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260617018262/en/ Antti Laitinen – You Are Here (2026), Maija Laitinen/Oulu2026 Already attracting international attention, Climate Clock offers a new public art experience connecting art, science and the northern landscape across the region. The trail opened to the public on 13 June 2026 across six locations: Yli-Ii, Oulu city centre, Ylikiiminki, Oulunsalo, Kiiminki
JTB to Acquire Asian DMC Leader EXO Travel for Accelerated Global Growth18.6.2026 04:00:00 CEST | Press release
— Advancing JTB's “Departing Globally, Arriving Globally” Vision — JTB Corp. today announced that it has reached an agreement to acquire all the shares of All Wise Holdings Pte. Ltd., the operator of Bangkok-based EXO Travel Group, a leading Destination Management Companies (DMCs) in Asia. The acquisition will be made through a JTB group company in the Asia-Pacific region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106801/en/ EXO Travel operates in the B2B market, primarily across Asia Pacific. For over 30 years, it has consistently maintained high customer satisfaction based on trust, achievements and high-quality service. The company has a strong brand presence in the affluent markets of Europe, North America and Australia, where the trust of partner companies contributes significantly to its value. Additionally, EXO Travel leverages its extensive network of destinations in Asia Pacific to develop strong products
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 01:01:00 CEST | Press release
The companies have entered into a multi-year research collaboration, option and licensing agreement in which LabGenius Therapeutics will leverage its AI/ML-driven antibody discovery platform,EVA™, to design and engineer next-generation multispecifics with enhanced therapeutic properties LabGenius Therapeutics will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory, and commercial milestones, along with royalties on net sales LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together,
Joe Vernachio Named President of SOREL18.6.2026 00:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom